NEW YORK (GenomeWeb News) – Applied Biosystems and its mass spectrometry joint venture partner, MDS Analytical Technologies, will collaborate with bioinformatics firm Premier Biosoft to develop integrated workflows for glycomics researchers, ABI said today.
Under the alliance, ABI and MDS will co-market and resell Premier Biosoft’s SimGlycan, a high-throughput glycan mass finger-printing tool, for use with their mass spectrometers including the 4800 Plus MALDI TOF/TOF Analyzer, the 4000 QTrap System, and the QStar Elite System. The SimGlycan predicts glycan structure using MS/MS data acquired by mass spectrometry.
"Protein glycosylation is one of the most common types of post-translational modifications," Lydia Nuwaysir, senior product manager at ABI, said in a statement. "Full characterization is particularly important for biopharmaceuticals because, ultimately, the type and extent of glycosylation can affect protein structure and activity.”
Terms of the alliance were not disclosed.